Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | TLR4 | O00206 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15051287 | 1.00 | APP (0.46) | APPHDAC1HDAC2TLR4TLR2 | |
| SCHEMBL13845994 | 0.82 | APP (0.50) | APPIDO1 | |
| SCHEMBL15050808 | 0.82 | APP (0.52) | APPIDO1 | |
| SCHEMBL15050807 | 0.82 | APP (0.52) | APPIDO1 | |
| SCHEMBL13845988 | 0.81 | APP (0.49) | APPIDO1 | |
| SCHEMBL106151 | 0.81 | PTGS1 (0.46) | PDE5AIDO1 | |
| SCHEMBL27851001 | 0.81 | PTGS1 (0.46) | PDE5AIDO1 | |
| SCHEMBL13846023 | 0.80 | APP (0.48) | APPHDAC1IDO1 | |
| SCHEMBL711600 | 0.79 | ALDH1A1 (0.40) | TLR4TLR2PDE5A | |
| SCHEMBL14002978 | 0.79 | CYP19A1 (0.52) | TLR4TLR2PDE5ATNNC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931332-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-03-19 | — | — | US | disclosed |
| CN-111419830-B | Phenylalkylcarbamate compounds for use in the prevention or treatment of epilepsy and epileptic related syndromes | 比皮艾思药物研发有限公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-4204395-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISEASE | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-05 | — | — | EP | disclosed |
| CN-115996905-A | Phenylalkyl carbamate compounds for use in preventing or treating neurodegenerative diseases | 生物药品解决方案有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-2968211-B1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO PHARM SOLUTIONS CO LTD (KR) | 2021-05-12 | — | — | EP | disclosed |
| CN-111419830-A | Phenylalkylcarbamate compounds for use in the prevention or treatment of epilepsy and epilepsy-related syndromes | 比皮艾思药物研发有限公司 | 2020-07-17 | — | — | CN | disclosed |
| EP-2797881-B1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | BIO PHARM SOLUTIONS CO LTD (KR) | 2018-11-14 | — | — | EP | disclosed |
| US-9504668-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-11-29 | — | — | US | disclosed |
| US-20160023999-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-01-28 | — | — | US | disclosed |
| CN-105209027-A | Phenylalkylcarbamate compounds for use in the prevention or treatment of epilepsy and epilepsy-related syndromes | BIO PHARM SOLUTIONS CO LTD | 2015-12-30 | — | — | CN | disclosed |
| US-9029589-B2 | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-05-12 | — | — | US | disclosed |
| US-20130165509-A1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165509-A1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | MYLK, PDE3A, TNNC1 | APP 2296/4885HDAC1 150/4885HDAC2 111/4885 |
| US-11931332-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | SNCA, MAPT, CHAT | APP 9/4885HDAC1 159/4885HDAC2 202/4885 |
| US-20160023999-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | SCN1A, GABARAPL1, NAA10 | APP 168/4885HDAC1 83/4885HDAC2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.